Flatiron Health at ASH 2025
Flatiron is excited to attend and present our research at the 2025 American Society of Hematology Annual Meeting, showcasing how our 6 new hematology Panoramic datasets and research capabilities generate real-world insights that guide treatment decisions, accelerate new development, and improve outcomes for patients with blood cancers. Come by our booth to interactively explore our new heme cohorts!
Get a preview of Panoramic Data from Dr. Emily Castellanos, Head of Research Oncology, Clinical Solutions at Flatiron
Flatiron is your trusted partner in delivering oncology evidence to support the evolving research questions across your hematology portfolio
505K+
patients with hematologic malignancies
6x
larger cohort sizes than previously available
250+
published pieces of hematology research
100+
research questions answered with custom data and services
Flatiron networking reception
Sunday, December 7, 2025
19:30-22:30
Join us for an evening of networking, cocktails, and hors d’oeuvres. This is a great opportunity to connect with colleagues, industry peers, and the Flatiron team.
Featured solutions
Hematology Panoramic data
Our recently launched hematology Panoramic data unlocks unprecedented scale, rich clinical details, and data interoperability to uncover insights into critical rare patient cohorts and novel therapies across the full patient journey. Come by our booth to interactively explore our heme cohorts!
Real-world data
Our flexible real-world data configurations are tailored to address the specific needs of your oncology portfolio and now encompass more than 5 million patient journeys, 4 of the largest oncology markets in the world, 22+ tumor types, and multimodal data.
Real-world evidence services
Flatiron’s in-house expertise and flexible engagement models can help you generate the insights and evidence you need to advance your lung cancer portfolio, from refining target product profiles, to conducting comparative effectiveness studies and supporting regulatory and HTA submissions.
Our research
Flatiron is excited to share our accepted research at this year’s conference.
Poster presentations
Use and outcomes following blinatumomab rechallenge in adolescents and young adults and adults with B-cell acute lymphoblastic leukemia (B-ALL)
Author affiliations: Stanford Cancer Institute, Tampa General Hospital Cancer Institute, Knight Cancer Institute, AstraZeneca, MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Flatiron Health
This study examines the real-world effects of reintroducing blinatumomab in patients with B-ALL who had previously received the therapy.
Read more
See this research
Publication Number: 1555
Date: December 6, 2025, 5:30 PM - 7:30 PM
connect with a flatiron expert
Anthony Proli
Clinical Director
Connect on Linkedin
What remains matters: Real-world impact of measurable residual disease testing in multiple myeloma
Author affiliations: Flatiron Health
This study leverages real-world data to better understand the adoption, testing patterns, and impact on treatment of MRD testing for patients with multiple myeloma in the real-world.
Read more
See this research
Publication Number: 2789
Date: December 6, 2025, 5:30 PM - 7:30 PM
connect with a flatiron expert
Senior Clinical Director
Connect on Linkedin
Biallelic TP53 alterations predict poorer survival in mantle cell lymphoma: Insights from a national real-world cohort
Author affiliations: University of Alabama Birmingham, Flatiron Health
This study explores the impact of TP53 mutations and del17p, examining different subgroups of TP53 and del17p alterations, with particular focus on the biallelic alterations subgroup.
See this research
Publication Number: 1830
Date: December 6, 2025, 5:30 PM - 7:30 PM
connect with a flatiron expert
Medical Director
Connect on Linkedin
Mediators of racial and ethnic inequities in access to front-line therapies for chronic lymphocytic leukemia in the United States: A real-world evidence study
Author affiliations: Rutgers Cancer Institute, Icahn School of Medicine at Mount Sinai, Mayo Clinic, BeOne Medicines, Mount Sinai Comprehensive Cancer Center, Flatiron Health
The study highlights critical inequities in access to cutting-edge CLL treatments, driven largely by structural barriers like neighborhood deprivation and lack of resources.
See this research
Publication Number: 2720
Date: December 6, 2025, 5:30 PM - 7:30 PM
connect with a flatiron expert
Olive Mbah
Senior Health Equity Scientist
Connect on Linkedin
Real-world treatment patterns and survival outcomes in second and third line settings in large B-cell lymphoma
Author affiliations: The University of Kansas Cancer Center, Memorial Sloan Kettering Cancer Center, Central Care Cancer Center, Kite, Flatiron Health
This study examines the effectiveness of CAR T therapy when compared to traditional treatments like R-ICE/DHAP across lines of therapy.
See this research
Publication Number: 4503
Date: December 7, 2025, 6:00 PM - 8:00 PM
connect with a flatiron expert
Anthony Proli
Clinical Director
Connect on Linkedin
Real-world insights into diffuse large B-cell lymphoma from EHR-derived data in Germany and the United Kingdom
Author affiliations: Flatiron Health
This study addresses critical gaps in existing data and highlights regional variations in treatment for patients with DLBCL in Germany and the UK.
See this research
Publication Number: 4487
Date: December 7, 2025, 6:00 PM - 8:00 PM
connect with a flatiron expert
Medical Director
Connect on Linkedin
Real-world measurable residual disease (MRD) testing patterns and associated outcomes in patients with Philadelphia-negative B-cell acute lymphoblastic leukemia
Author affiliations: Flatiron Health
This study uses real-world data to examine the use of MRD testing, including the timing and frequency of testing, in Philadelphia-negative B-cell acute lymphoblastic leukemia and its impact on patient outcomes.
See this research
Publication Number: 4484
Date: December 7, 2025, 6:00 PM - 8:00 PM
connect with a flatiron expert
Clinical Director
Connect on Linkedin
Real-world treatment patterns and clinical outcomes in high-risk mantle cell lymphoma: A retrospective analysis
Author affiliations: The University of Texas MD Anderson Cancer Center, AstraZeneca, City of Hope Comprehensive Cancer Center, Flatiron Health
This study improves understanding of the characteristics and outcomes of high-risk MCL patients, specifically looking at the impact of TP53 mutations, high Ki67 proliferation index, or aggressive morphology.
See this research
Publication Number: 4482
Date: December 7, 2025, 6:00 PM - 8:00 PM
connect with a flatiron expert
Senior Medical Director
Beyond the trial: Real-world CRS, ICANS, and healthcare burden of CAR T-cell therapy across US oncology practices
Author affiliations: Moffitt Cancer Center, Flatiron Health
This study evaluates the real-world prevalence of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome in patients receiving CAR T and assesses their associated healthcare burden.
See this research
Publication Number: 6263
Date: December 8, 2025, 6:00 PM - 8:00 PM
connect with a flatiron expert
Senior Clinical Director
Connect on Linkedin
Barriers and bridges: real-world CAR T delivery across US oncology practices
Author affiliations: Moffitt Cancer Center, Flatiron Health
This study leverages real-world data to better understand the utilization, referral patterns, and access to CAR T therapy in the real-world.
See this research
Publication Number: 6263
Date: December 8, 2025, 6:00 PM - 8:00 PM
connect with a flatiron expert
Senior Medical Director
Real-world insights into multiple myeloma management: An analysis of EHR-derived data in the UK and Germany
Author affiliations: Flatiron Health
This study addresses critical gaps in existing data and highlights regional variations in treatment for patients with multiple myeloma in Germany and the UK.
See this research
Online only
connect with a flatiron expert
Medical Director
Connect on Linkedin
The bispecific blind spot: Uncovering real-world inequities in diffuse large B-cell lymphoma, follicular lymphoma, and multiple myeloma therapy access
Author affiliations: Flatiron Health
This study explores demographic and systemic factors contributing to inequities in multiple blood cancers, revealing significant gaps in therapy access among different patient populations.
See this research
Online only
connect with a flatiron expert
Senior Health Equity Scientist
Connect on Linkedin